Terms: = Ovarian cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
41 results:
1. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Kim SI; Joung JG; Kim YN; Park J; Park E; Kim JW; Lee S; Lee JB; Kim S; Choi CH; Kim HS; Lim J; Chung J; Kim BG; Lee JY
Gynecol Oncol; 2024 Mar; 182():7-14. PubMed ID: 38246047
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced ovarian cancer (GEICO-89T/MINOVA Study).
Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
[TBL] [Abstract] [Full Text] [Related]
3. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
Simonelli M; Garralda E; Eskens F; Gil-Martin M; Yen CJ; Obermannova R; Chao Y; Lonardi S; Melichar B; Moreno V; Yu ML; Bongiovanni A; Calvo E; Rottey S; Machiels JP; Gonzalez-Martin A; Paz-Ares L; Chang CL; Mason W; Lin CC; Reardon DA; Vieito M; Santoro A; Meng R; Abbadessa G; Menas F; Lee H; Liu Q; Combeau C; Ternes N; Ziti-Ljajic S; Massard C
ESMO Open; 2022 Oct; 7(5):100562. PubMed ID: 35987165
[TBL] [Abstract] [Full Text] [Related]
4. Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/foxp3 signaling pathway in ovarian cancer cells.
Shan Y; Zhang B; Chen L; Zhang H; Jiang C; You Q; Li Y; Han H; Zhu J
Anticancer Drugs; 2023 Jan; 34(1):73-80. PubMed ID: 35946515
[TBL] [Abstract] [Full Text] [Related]
5. Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract] [Full Text] [Related]
6. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous ovarian cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
Sue-A-Quan R; Patel PG; Shakfa N; Nyi MN; Afriyie-Asante A; Kang EY; Köbel M; Koti M
Gynecol Oncol; 2021 Aug; 162(2):421-430. PubMed ID: 34088514
[TBL] [Abstract] [Full Text] [Related]
8. Tumor immune microenvironment in brain metastases from gynecologic malignancies.
Gill CM; D'Andrea MR; Tomita S; Suhner J; Umphlett M; Zakashansky K; Blank SV; Tsankova N; Shrivastava RK; Fowkes M; Kolev V
Cancer Immunol Immunother; 2021 Oct; 70(10):2951-2960. PubMed ID: 33713153
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress ovarian cancer cell progression.
Jiang R; Zhang H; Zhou J; Wang J; Xu Y; Zhang H; Gu Y; Fu F; Shen Y; Zhang G; Feng L; Zhang X; Chen Y; Shen F
Cell Death Dis; 2021 Feb; 12(2):145. PubMed ID: 33542185
[TBL] [Abstract] [Full Text] [Related]
10. The investigation of T-cell receptor subtypes in ovarian cancer: effects on survival and prognostic factors.
Özkan S; Selvi Gunel N; Aygünes D; Akman L; Yildirim N; Teti K Vardarli A; Özsaran A; Terek C
J Obstet Gynaecol; 2021 Aug; 41(6):951-955. PubMed ID: 33228419
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
Jäntti T; Luhtala S; Mäenpää J; Staff S
Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
[TBL] [Abstract] [Full Text] [Related]
12. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.
van den Ende T; van den Boorn HG; Hoonhout NM; van Etten-Jamaludin FS; Meijer SL; Derks S; de Gruijl TD; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188386. PubMed ID: 32540465
[TBL] [Abstract] [Full Text] [Related]
13. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
Wolf D; Fiegl H; Zeimet AG; Wieser V; Marth C; Sprung S; Sopper S; Hartmann G; Reimer D; Boesch M
Int J Cancer; 2020 Apr; 146(7):2007-2018. PubMed ID: 31800094
[TBL] [Abstract] [Full Text] [Related]
14. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous ovarian cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract] [Full Text] [Related]
15. Characterization and Comparison of GITR Expression in Solid Tumors.
Vence L; Bucktrout SL; Fernandez Curbelo I; Blando J; Smith BM; Mahne AE; Lin JC; Park T; Pascua E; Sai T; Chaparro-Riggers J; Subudhi SK; Scutti JB; Higa MG; Zhao H; Yadav SS; Maitra A; Wistuba II; Allison JP; Sharma P
Clin Cancer Res; 2019 Nov; 25(21):6501-6510. PubMed ID: 31358539
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes.
Dutsch-Wicherek MM; Szubert S; Dziobek K; Wisniewski M; Lukaszewska E; Wicherek L; Jozwicki W; Rokita W; Koper K
Ginekol Pol; 2019; 90(4):179-184. PubMed ID: 31059109
[TBL] [Abstract] [Full Text] [Related]
17. Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: Preliminary results.
Wu M; Chen X; Lou J; Zhang S; Zhang X; Huang L; Sun R; Huang P; Pan S; Wang F
Int Immunopharmacol; 2017 Jun; 47():244-250. PubMed ID: 28437737
[TBL] [Abstract] [Full Text] [Related]
18. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer.
Chen X; Oppenheim JJ
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096506
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-ovarian High-Grade Serous Carcinoma.
Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
[TBL] [Abstract] [Full Text] [Related]
20. Kaempferol enhances the suppressive function of Treg cells by inhibiting foxp3 phosphorylation.
Lin F; Luo X; Tsun A; Li Z; Li D; Li B
Int Immunopharmacol; 2015 Oct; 28(2):859-65. PubMed ID: 25870037
[TBL] [Abstract] [Full Text] [Related]
[Next]
